Trials / Unknown
UnknownNCT03189901
Early Management Strategies of Acute Heart Failure for Patients With NSTEMI
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 470 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
There are always poor outcomes in patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level. An elevated BNP/NT-proBNP level highly indicates acute heart failure(AHF).Levosimendan is recommended in many clinical trials of heart failure and Chinese heart failure guidelines. As a result, the investigators form a hypothesis that when patients with AMI combined with elevated BNP/NT-proBNP level are in conditions before AHF, to use levosimendan may reduces the risk of heart failure and improve the outcome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Regular management+Levosimendan | Patients are treated with regular management recommended in guidelines and levosimendan. |
Timeline
- Start date
- 2017-07-01
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2017-06-16
- Last updated
- 2021-07-19
Locations
14 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03189901. Inclusion in this directory is not an endorsement.